Australian firm Starpharma Holdings has announced the appointment of Justin Cahill as Chief Financial Officer (CFO) and Company Secretary, following an extensive executive search process.
MELBOURNE, Australia, Sept. 12, 2022 /PRNewswire/ -- Cabazitaxel (Jevtana, Sanofi) is a market leading chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian biotech company Starpharma, DEP® cabazitaxel is a patented, highly water soluble dendrimer nanoparticle version of standard cabazitaxel which has shown, in preclinical and clinical studies, benefits in terms of safety and efficacy.
Merck has tightened its ties to Starpharma as it continues to build out its antibody-drug conjugate (ADC) capabilities, signing a second agreement that will enable it to evaluate candidates based on a dendrimer drug delivery platform.
Starpharma signs new DEP research agreement with MSD
Starpharma signs new DEP agreement with MSD
Australia-based Starpharma has announced that SPL7013, the antiviral agent in VIRALEZE nasal spray, achieved 95% and 99.7% reduction in viral infectivity against two significant types of influenza virus, A and B, respectively, in virucidal assays.
In a major development for its VIRALEZE™ antiviral nasal spray, Australia-based Starpharma has announced that its potent antiviral agent, SPL7013, achieved the maximum possible virucidal effect against the highly transmissible Omicron variant of SARS-CoV-2.
Starpharma has reported positive interim data from the prostate cancer arm of the Phase II trial of its clinical-stage asset, DEP cabazitaxel.
CHICAGO (Reuters) - Pfizer PFE.N and BioNTech's BNTX.O COVID-19 vaccine is safe, effective and produces robust antibody responses in 12- to 15-year olds, the companies said on Wednesday, paving the way for them to seek U.S. and European approval to use the shot in this age group within weeks.
MELBOURNE, Australia, Sept. 15, 2021 /PRNewswire/ -- DEP® cabazitaxel is a proprietary nanoparticle version of leading prostate cancer drug cabazitaxel (Jevtana®), which had global sales of US$536 million in 2020. Starpharma's DEP® cabazitaxel is a water soluble, polysorbate-80 free formulation, without requirement for pre-treatment with steroids nor G-CSF to reduce the risk of severe bone marrow toxicity.